Erard Veronique, Huang Meei-Li, Ferrenberg James, Nguy Long, Stevens-Ayers Terry L, Hackman Robert C, Corey Lawrence, Boeckh Michael
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA.
Clin Infect Dis. 2007 Oct 15;45(8):958-65. doi: 10.1086/521851. Epub 2007 Sep 6.
The value of adenovirus plasma DNA detection as an indicator for adenovirus disease is unknown in the context of T cell-replete hematopoietic cell transplantation, of which adenovirus disease is an uncommon but serious complication.
Three groups of 62 T cell-replete hematopoietic cell transplant recipients were selected and tested for adenovirus in plasma by polymerase chain reaction.
Adenovirus was detected in 21 (87.5%) of 24 patients with proven adenovirus disease (group 1), in 4 (21%) of 19 patients who shed adenovirus (group 2), and in 1 (10.5%) of 19 uninfected control patients. The maximum viral load was significantly higher in group 1 (median maximum viral load, 6.3x10(6) copies/mL; range, 0 to 1.0x10(9) copies/mL) than in group 2 (median maximum viral load, 0 copies/mL; range, 0 to 1.7x10(8) copies/mL; P<.001) and in group 3 (median maximum viral load, 0 copies/mL; range 0-40 copies/mL; P<.001). All patients in group 2 who developed adenoviremia had symptoms compatible with adenovirus disease (i.e., possible disease). A minimal plasma viral load of 10(3) copies/mL was detected in all patients with proven or possible disease. Adenoviremia was detectable at a median of 19.5 days (range, 8-48 days) and 24 days (range, 9-41 days) before death for patients with proven and possible adenovirus disease, respectively.
Sustained or high-level adenoviremia appears to be a specific and sensitive indicator of adenovirus disease after T cell-replete hematopoietic cell transplantation. In the context of low prevalence of adenovirus disease, the use of polymerase chain reaction of plasma specimens to detect virus might be a valuable tool to identify and treat patients at risk for viral invasive disease.
在T细胞充足的造血细胞移植中,腺病毒血浆DNA检测作为腺病毒疾病指标的价值尚不清楚,而腺病毒疾病是一种罕见但严重的并发症。
选取三组共62例T细胞充足的造血细胞移植受者,通过聚合酶链反应检测血浆中的腺病毒。
在24例确诊腺病毒疾病的患者中,21例(87.5%)检测到腺病毒(第1组);在19例排出腺病毒的患者中,4例(21%)检测到腺病毒(第2组);在19例未感染的对照患者中,1例(10.5%)检测到腺病毒。第1组的最大病毒载量显著高于第2组(最大病毒载量中位数为6.3×10⁶拷贝/毫升;范围为0至1.0×10⁹拷贝/毫升)(第2组最大病毒载量中位数为0拷贝/毫升;范围为0至1.7×10⁸拷贝/毫升;P<0.001)和第3组(最大病毒载量中位数为0拷贝/毫升;范围为0至40拷贝/毫升;P<0.001)。第2组中所有发生腺病毒血症的患者均出现与腺病毒疾病相符的症状(即可能患有疾病)。在所有确诊或可能患有疾病的患者中均检测到最低血浆病毒载量为10³拷贝/毫升。确诊和可能患有腺病毒疾病的患者在死亡前,腺病毒血症分别在中位数19.5天(范围为8至48天)和24天(范围为9至41天)时可检测到。
持续或高水平的腺病毒血症似乎是T细胞充足的造血细胞移植后腺病毒疾病的一个特异性和敏感性指标。在腺病毒疾病患病率较低的情况下,利用血浆标本的聚合酶链反应检测病毒可能是识别和治疗有病毒侵袭性疾病风险患者的一种有价值的工具。